Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 6, Pages 841
Publisher
MDPI AG
Online
2019-06-19
DOI
10.3390/cancers11060841
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma
- (2019) Ghassan K Abou-Alfa LANCET ONCOLOGY
- Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey
- (2018) Jennifer Gill et al. Future Oncology
- Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC
- (2018) K. J. Hartrumpf et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
- (2018) Pierce K.H. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-Related Quality of Life Comparisons After Radical Therapy for Early-Stage Hepatocellular Carcinoma
- (2018) Q. He et al. TRANSPLANTATION PROCEEDINGS
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Review article: systemic treatment of hepatocellular carcinoma
- (2018) Matthias Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
- (2018) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
- (2018) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
- (2017) Ian Chau et al. EUROPEAN JOURNAL OF CANCER
- The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
- (2017) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
- (2017) Jennifer Eatrides et al. Cancer Control
- Medical Management of Hepatocellular Carcinoma
- (2017) Nicole E. Rich et al. Journal of Oncology Practice
- Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial
- (2016) Mihir Gandhi et al. BMC CANCER
- Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment
- (2016) Masako Shomura et al. BMC CANCER
- Quality of Life of Patients with Cancer: A Determinant of the Quality of Life of Their Family Caregivers
- (2016) Gadiraju Padmaja et al. JOURNAL OF CANCER EDUCATION
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
- (2016) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-Related Quality of Life and Psychological Distress in Patients With Early-Stage Hepatocellular Carcinoma After Hepatic Resection or Transplantation
- (2016) J.Y. Lei et al. TRANSPLANTATION PROCEEDINGS
- Development and novel therapeutics in hepatocellular carcinoma: a review
- (2016) Pravinkumar Vishwanath Ingle et al. Therapeutics and Clinical Risk Management
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Quality of life changes in patients undergoing treatment for hepatocellular carcinoma
- (2015) Wei-Chu Chie et al. QUALITY OF LIFE RESEARCH
- The Changing Landscape of Hepatocellular Carcinoma
- (2014) Erik S. Knudsen et al. AMERICAN JOURNAL OF PATHOLOGY
- Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas
- (2014) G. Huang et al. BRITISH JOURNAL OF SURGERY
- Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
- (2014) Hashem B. El-Serag et al. HEPATOLOGY
- Management of hepatocellular carcinoma
- (2014) P. Fitzmorris et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Epidemiology of Hepatocellular Carcinoma
- (2013) Sahil Mittal et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Surgery on Quality of Life in Patients with Hepatocellular Carcinoma
- (2013) Yoshihiro Mise et al. WORLD JOURNAL OF SURGERY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions
- (2012) Paola Rita Brunocilla et al. MEDICAL ONCOLOGY
- Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer
- (2012) David Cella et al. QUALITY OF LIFE RESEARCH
- The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
- (2011) Katherine A. McGlynn et al. Clinics in Liver Disease
- International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life ques
- (2011) Wei-Chu Chie et al. HEPATOLOGY
- Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment
- (2011) Adriana Toro et al. SURGICAL ONCOLOGY-OXFORD
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials
- (2008) Franck Bonnetain et al. QUALITY OF LIFE RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now